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CHAPTER I 
INTRODUCTION 
Through the ages man has tried to conquer disease with his scientific 
knowledge and ability. In the treatment of neoplastic diseases many 
chemotherapeutic agents have been introduced which have resulted in varying 
degrees of success. One such group of agents, the folic acid antagonists, 
has been utilized for the past twenty years in cancer chemotherapy. 
Today, methotrexate is the most widely used member of this group of agents • 
. 
However, as is the case with most anti-neoplastic drugs, the concomitant 
side effects that occur with therapeutic doses have limited its optimum 
utilization. 
The complaint of a sore, painful mouth with a hyperemic appearance is 
a well-known side effect from methotrexate therapy. Many hematologists 
use the oral mucosa as a general indicator of the therapeutic effectiveness 
of this drug. Once the stomatitis has appeared, the drug is discontinued, 
and it is assumed that the optimal drug effect has been attained. Of 
course, regular hematologic studies and analyses are performed in conjunction 
with the therapy. 
Although the modern medical literature contains many case reports 
and experimental investigations concerning the activity of methotrexate, 
very little is to be found regarding the specific dynamic effect on the 
1 
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oral epithelium. In ordei to study this effect, the autoradiographic 
technique has been employed in this study. This technique has previously 
been utilized to measure the turnover rate of various other tissues through-
out the body, but has never been used on the oral epithelium for this 
purpose. 
CHAPTER II 
REVIEW OF THE LITERATURE 
A. Methotrexate 
Physical Properties 
The chemical processes of life occur continuously in all living or-
ganisms with the aid of special proteins, the enzymes. These react with 
food substances and with small molecules arising from these substances, 
which are termed metabolites. Huennekens and Osborn (1959) stated that 
coenzymes, including certain vitamins as folic acid, are metabolites which 
. 
are present in only very small amounts in living tissues, but are essential 
for normal and continued function of the tissues. Stokstad (1954) men-
tioned that deficiency states of folic acid were described in man, monkeys, 
chicks, rats, guinea pigs, insects and microorganisms long before the 
vitamin was isolated and characterized. 
Willis, et al, (1931) in Bombay attempted to identify a factor in 
yeast autolysate and crude liver extract which prevented some forms of 
megaloblastic anemia. Pfiffner, et al, (1934, 1944) were the first to 
isolate folic acid, or more exactly, pteroylglutamic acid (PGA). (Fig. la) 
Angier, Subbarow (1946) and their group at Lederle Laboratories found 
that a growth factor for Lactobacillus casei was similar, if not identical, 
to the factor above. They were able to determine its constitution and 
were the first to synthesize it. 
3 
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Bessey (1953) stated that the vitamin folic acid has been shown to be 
essential in cells for their normal growth, maintenance, and functioning 
of their cellular processes. These reactions can be blocked by certain 
chemicals which displace metabolites from enzymic reactions, thereby in-
terfering with biochemical processes. 
Delmonte and Jukes (1962) noted that the folic acid antagonists owe 
their profound biological activities to their ability to compete with the 
vitamin folic acid. These metab9lic antagonists, such as methotrexate and 
aminopterin, are very similar in molecular structure to folic acid, except 
for the presence of additional chemical group(s). 
Seeger, et al (1947) were the first to synthesize certain derivatives 
of folic acid, namely aminoproterin and amethopterin. The brand name of 
amethopterin is methotrexate. 
In aminopterin the folic acid hydroxyl group in the 4-position of the 
pteridine ring is replaced by an amino group, thereby giving this folic 
acid antagonist its potency. The chemical name for aminopterin is 4-aminop-
. teroylglutamic acid. (Fig. lb). Methotrexate has in addition a methyl 
group on the amino nitrogen between the pteroyl and benzoyl group and is 
named 4-amino-N10-methylpteroylglutamic acid. (Fig. le) 
Rall (1963) described methotrexate as a moderately large molecule 
with a molecular weight of 454.4. It is fairly soluble as the salt in 
aqueous solution, but is insoluble in lipoid solvents at body pH. The two 
carboxyl groups in the glutamic acid portion of the molecule render it a 
fairly strong acid. Furthermore, the amino group (NH2) on the pteridine 
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ring can ionize to a limited extent as a weak base. In general, this des-
cription resembles that of penicillin. Therefore, he concluded that after 
methotrexate ingestion there would be a limited degree of oral absorption, 
a volume of distribution largely confined to the extracellular spaces, and 
a limited penetration into the cerebralspinal fluid and brain. 
The molecular chemistry of the pteridines is complex and the separa-
tion of related compounds has been very difficult. Oliver (1961) was only 
able to attain an eighty-five per cent degree of purity of methotrexate. 
Distribution and Fate of Methotrexate 
In order to understand the action of methotrexate in the body, one 
must first strictly define its tisstle distribution. Methotrexate has been 
observed to persist in human liver, kidney and spleen. These tissues have 
been attributed by Dietrich et al (1952) to normally have a high folic acid 
and citrovorum factor. 
Timmis (1967) stated that when folic acid is reduced and formylated, 
and the product is treated with alkali, 5-formyltetrah.ydrofolic acid is 
produced. It is also known as folinic acid leucovorum or citrovorum 
factor and is used as the most effective antidote against methotrexate 
toxicity. 
Cherache (1960) and Freeman (1958) both concluded that the duration 
and amount of drug persistence are independent of the dosage, route of 
administration and duration of drug therapy. 
Condit (1957, 1960) with human subjects, and Rall (1959) with rats 
and dogs showed that better absorption and maintenance of drug blood levels 
• 
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were obtained with repeated small doses rather than with single large 
doses. However, drug toxicity also increases when this method of intake is 
utilized. 
. 
Berlin(l963) suggested that some of the drug does penetrate cells 
since the folic reductase system is intracellular. 
Fountain et al (1953) used bioautographs to show that high concentra-
tions of methotrexate persist in the tissues of the normal mouse (20 grams) 
for a period of three weeks and, in one instance, as long as eight months 
in the liver. A decrease in kidney concentration of methotrexate was also 
noted within 24 hours. The mouse rapidly eliminated all the methotrexate 
in excess of its renal threshold. He assumed that the methotrexate which 
was retained for such long periods of time was incorporated up to a rela-
tively constant concentration in enzymes ordinarily associated with folic 
acid and citrovorum factor and any excess was rapidly excreted. 
More recently, Henderson and Oliverio (1965) studied several different 
groups of male mice with various dosages of tritiated methotrexate. In the 
first group, 15 mg/kg was given and they observed that after twenty-four 
hours, most of it had been excreted with the remainder being distributed 
throughout the body tissues. Only the liver, kidney, stomach and gonads 
consistently contained greater quantities of radioactivity than did the 
remaining organs of comparable size. The bulk of the drug was excreted in 
the urine, and about 15 per cent appeared in the feces, apparently derived 
from biliary excretion. The urinary excretion was over 50 per cent in 
four hours after injection and 60 - 80 per cent by eight hours. At the end 
of the twenty-four (24) hour period, almost all of the original dose was 
7 
recovered. This confirmed the earlier findings of Werkheiser (1963) who sta-
ted that methotrexate was excreted fairly rapidly through renal pathways 
also that some biliary excretion occurred. The second group was pre-
treated for five days with 0.5 mg/kg/day of unlabeled methotrexate. This 
did not significantly alter the pattern of excretion, although total recovery 
of the drug was slightly reduced. A third group was administered 0.5 mg/kg 
of tritiated methotrexate for six consecutive days. However, this too 
failed to change the total amount of retained radioactivity or the propor-
tions in the fractions obtained. The relatively constant proportions in 
the counts in each fraction of liver tissue appeared to reflect the dynamic 
equilibrium between subcellular components rather than binding sites with 
either sequential or variable priority for the drug. The majority of the 
remaining labeled methotrexate was precipitated with the nucleus and stromal 
elements during the 600 times "g" centrifugation. 
The distribution in the liver was similar to that reported by Werk-
heiser (1961) and is consistent with his proposal that methotrexate binds 
to the enzyme folic reductase which resides in the soluble fraction of 
1i ver cells. 
Since the antagonists are essentially irreversibly bound to folic 
reductase, Werkheiser (1962) suggested that the drug remains in the cell 
until the cell's death and removal from the body; and that the half-times 
represent an estimate of the turnover of the two populations of cells in 
the liver, and of the turnover in the intestinal mucosal cells. 
8 
Henderson et al (1965) established that about fifty per cent of me-
thotrexate in mouse plasma was reversibly bound to proteins. The majority 
of this binding was associated with the albumin fraction, but its stability 
has not been determined. However, they felt that the degree of this binding 
was relatively constant over a remarkably wide range of concentration. 
Johns (1961) found a similar degree of protein binding with tritiated 
folic acid. Johns et al (1964) performed in vivo studies indirectly com-
paring the affinity of a variety of folic analogs for folic reductase, and 
this resulted in the following ranking as far as their ability to displace 
bound tritiated methotrexate: methotrexate dihydrofolic acid folic acid 
formyl tetrahydrofolic acid methyl.tetrahydrofolic acid. 
Fischer (1962) and Wood et al (1961) have demonstrated a possible 
active transport mehcanism for methotrexate absorption. 
In a recent experiment, Condit and Yoshino (1968) studied the dis-
placement of 0.1 mg/kg of tritiated methotrexate by three compounds. They 
observed that after injection of tritiatiated methotrexate, the total 
radioactivity in the small intestine disappeared more rapidly than from the 
liver and kidney. Displacement of tritiated methotrexate from these three 
tissues increased following increasing doses of unlabeled methotrexate 
until almost all of the radioactivity in the organs was displaced by 10 mg/kg 
of unlabeled methotrexate. A dose of 25 mg/kg of folic acid displaced 25 
per cent of tritiated methotrexate from the liver, but the same amount of 
citrovorum factor failed to displace any isotope. 
9 
Their chromatographic studies of the intestine revealed almost all 
the radiation tritiated methotrexate remained unchanged. The liver homo-
genate yielded a large peak of bound-form isotope, a relatively small 
.peak of free tritiated methotrexate, and a very small peak of an unknown 
metabolite. 
There is no evidence that methotrexate is metabolized in any mammals. 
Whatever amount is not bound by the folic reductase is excreted unchanged. 
Mechanism of Action 
Biochemical Alterations 
Friedkin (1963) noted that the enzyme folic reductase, or as it is 
also known, dihydrofolic reductase; specifically catalyzed the reduction 
of folic acid to tetrahydrofolic acid and that in folic acid biosynthesis 
the dihydro form was the final product. Brown, Weisman and Molmar (1961) 
established that dihydrofolic acid was the initial compound required for 
the biosynthesis of tetrahydrofolic acid and its derivatives. 
Tetrahydrofolic acid (FAH4) is involved in the transfer of single 
carbon units in biochemical rea~tions involving the de ~ synthesis of 
purines and pyrimidines, such as thymine, methionine, and serine, which 
eventually lead to the synthesis of nucleic acids. 
Demonte and Jukes (1962) stated that mehtotrexate's usefulness is 
primarily due to the firm combination with th~ folic reductase system, 
thereby interferEi,ing with these biosynthetic pathways among which is the 
synthesis of thymidylic acid which leads to DNA. (fig. 2). Methotrexate 
is not reduced by the folic reductase system and once it has combined with 
the enzyme, the antagonist takes no further part in the biochemistry of cells 
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Mead (1963) felt that folic reductase was inhibited by a number of 
folic acid analogs. Through this inhibition, methotrexate and the other 
analogs could cause a depletion of various coenzyme forms, thereby reduc-
ing activity in the biosynthetic pathways which utilize them. 
Mead also stated that the de ~ biosynthesis of purines started 
with ribose-5-Po4 , and constructed the purine nucleus, step by step, to 
form the purine nucleotide inosinic acid. Two tetrahydrofolate enzymes are 
involved in this sequence, each contributing a one-carbon unit at the 
oxidation level of formate to the final purine nucleus. In this instance, 
methotrexate interfered with this biosynthetic pathway by inhibiting the 
folic reductase which supplies the two tetrahydrofolate enzymes. 
Another key biochemical pathway known to be inhibited by folic acid 
antagonists is the biosynthesis of thymidylic acid which is essential for 
the synthesis of desoxyribonucleic acid (DNA). Here the enzyme thymidylate 
synthetase was found by Wahba and Friedkin (1961) to transfer a one-carbon 
unit from mehtylenetetrahydrofolate (from folic acid activation) to 
deoxyuridylic acid. The products of the reaction are thymidylic acid and 
dihydrofolic acid. (Fig. 3). 
McDougall and Blakeley (1961) proposed that methotrexate, as is true 
of all folic acid antagonists, exerted an indirect inhibitory effect on 
this reaction by blocking dihydrofolate reductase. That is, since the folic 
~cid cycle is dependent upon the regeneration of tetrahydrofolate from 
dihydrofolate, the inhibition of the reductase prevented further formation 
of methylenetetrahydrofolate and the overall effect was an inhibition of 
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thymidylate synthetase. (Fig. 3). This is in contrast to the direct in-
hibition of thymidylate·synthetase by the fluorinated pyrimidines, which 
has been established by Hartmann and Heidelberger (1961). 
A similar indirect inhibition by methotrexate occurs in the synthesis 
of methionine as reported by Larrabee (1961). 
Thus many of the effects of methotrexate can be explained by the in-
hibition of folic acid reduction, both with respect to its highly spcific 
tissue toxicity and to its pharmacologic effects. 
Werkheiser (1961) illustrated the affinity of methotrexate for the 
enzyme folic reductase by the fact that nearly eighty per cent of its 
activity remained in the supernatant•after sucrose fractionation of treated 
rat liver. He also showed that the affinity of the partially purified 
folic reductase for methotrexate was about 100,000 times greater than for 
folic acid at pH 6.0 and 20,000 times as great for dihydrofolic acid at 
pH 7.5. Therefore, the enzyme was quickly saturated by the inhibitor, lead-
ing to pseudoirreversibility and the exclusion of folic acid from the 
enzyme. This strength of association between the drug and the enzyme was 
so great that the drug acted as a titrating agent. 
Werkheiser (1961) used the term "stoichiometric" to describe this in-
hibition, since the amount of methotrexate bound by the soluble supernatant 
proteins of the rat liver was claimed to be precisely the amount required 
to inhibit the folic reductase in the preparation. This allowed a titra-
tion of enzyme with drug. Removal of the drug from the protein by dialysis 
against folic acid resulted in precisely equivalent reactivation of the 
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enzyme. He concluded that folic reductase was the agent in rat liver which 
binded the 4-arnino derivatives of folic acid, both in vivo and in vitro, 
and thus probably represented the mechanism of long term retention of 
these drugs in the animal. 
Using this procedure he showed that about half of the methotrexate 
which was retained in mouse liver twenty-four (24) hours after a single 
injection was lost very slowly. He arrived at a half-time of over ninety 
days. This work confirmed the findings of Fountain (1953) and Cherache 
et al (1960). Werkheiser felt that this stoichiometric relationship indi-
cated that methotrexate was a very potent inhibitor of folic reductase 
and that within twenty-four (24) hours no free drug was available to in-
hibit any other enzyme. 
Timmis (1967) stated that subsequent work on the drug-enzyme relation-
ship and their interaction indicated that the binding of the drug to 
protein was more than could be accounted for by the amount of folic reduc-
tase present. This suggested that binding to non-specific protein may be 
a prerequisite of the metabolism of folic acid and its antagonists. 
Condit (1961) suggested that the activity of methotrexate was mediated 
by some additional mechanism. In 1965 he confirmed that the antifolics had 
important sites of action in addition to inhibiting folic reductase. He 
noted the blockage of folic reductase in mouse liver by aminopterin and 
methotrexate with in vivo doses of 0.1 mg/kg. 
Werkheiser (1963) elaborated on the ever present reality of auxillary 
problems which are associated with methotrexate therapy and its success 
and failure. These included the drug's side effects on the host, chemical 
•• 
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modifications of the drug to make more effective agents, special excre-
torjr mechanisms, limitations of access of the drug to its site of action 
due to permeability or active transport restrictions, intracellular com-
partmentation of the drug, and rate of recove:rry- from the drug's effect. 
These problems are recognized, but as yet unsolved, and he felt that 
they should be considered when evaluating the therapeutic efficacy and 
the success of methotrexate treatment. 
In addition to the above, the in.~ibition of f olic reductase by 
methotrexate has also been well documented by Osborn et al (1958), 
Peters (1958), and Zakrzewski (1960). 
To understand the exact intracellular action of methotrexate, it 
is convenient to observe the course of events following a single dose of 
methotrexate as described by Werkheiser (1963). The drug enters the 
cell rather rapidly, perhaps in amounts in excess of that needed to abo-
lish folic reductase activity. The resulting effect is a profound in-
hibition of thymine synthesis with a lesser but still very strong inhi-
bition of purine _ synthesis. 
Thiersch, et al (1949) found by microscopic observation that pro-
tein synthesis continued during a period of obvious methotrexate toxicity; 
yet the cells were inhibited by the drug. He observed increased cyto-
plasmic volume microscopically. Van Scott (1959) noted enlarged epithe-
lial tonofibrils in the epithelialization of psoriatic patients treated 
with methotrexate. These observations led Werkheiser (1963) to deduce 
that there was a continuation of protein synthesis during a period of 
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obvious methotrexate toxicity. Therefore, he concluded that the presence 
of the drug in a cell causes an abrupt cessation of multiplication, but 
permits a moderate synthesis of proteins, including that of folic reduc-
tase. Hakala (1962) showed that this enzyme could be synthesized at a 
significant rate by the fact that the inhibitory level of methotrexate 
for resistant S-180 cells in culture was determined by the balance between 
the rate of drug entry and the rate of enzyme synthesis. Hence, if the 
supply of this critical enzyme has been replenished, the cells recover 
and resu~e mitosis. 
The free drug in the cell now has two alternate pathways open to 
it. Fischer (1962) found that part of it will pass out of the cell at a 
relative1y slow rate, while part of it will conibine with newly formed 
enzyme. When enough free enzyme is present, normal division processes 
would resume provided that the activity of folic reductase had not been 
abolished for twenty-four hours or more. Such cells would suffer irre-
versible damage. 
Werkheiser (1962; et al 1963) found that a particular dose of the 
drug,which was high enough to inactivate al.l the enzyme that could be 
found during the critical period, was so closely related with the toxicity 
and the tumor sensitivity. He also determined that the dose necessary to 
reduce the free enzyme level of the intestinal mucosa to negligible levels 
was almost precisely the LD50 • 
Fisher (1962) and Werkheiser (1962) both proposed that the primary 
parameter for defining the sensitivity of a tissue to methotrexate would 
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be the rate of entry of the drug into that tissue. Therefore, they felt 
that other phenomen;i. besides the level of the enzyme in the tissue were 
responsible for the effect of this drug on different tissues. 
As long as free drug exists, activity of folic reductase would be 
abolished. During this time no tetrabydrofolate could be formed from 
dibydrofolate. For non-dividing tissues such as liver and kidney, this 
would be of little consequence, since these tissues have large stores of 
tetrabydrofolate compounds. However, rapidly dividing tissues, for exam-
ple, intestinal mucosa, bone marrow, oral mucosa, and tumors, contain 
much smaller amounts of tetrabydrofolate compounds (Nichol, 1953), but 
continue to oxidize them to dibydrofolate in the process of thyrnidylate 
synthesis. Therefore, Werkheiser (1963) explained that these tissues 
could become depleted of their stores of reduced folate cofactors quite 
readily, despite the normal circulating blood level of these compounds, 
which apparently is too low. If this situation were maintained, they 
would undergo "thyrnineless death" as Cohen (1956) has described. 
Both Werkheiser (1961) and Williams (1955) established that the 
synthesis of thyrnidylate appeared to be more sensitive to the action of 
methotrexate than were the other reactions requiring tetrabydrof olate. 
Since Werkheiser et al (1963) showed that the rate of methotrexate 
entering cells differs from one tissue to another, a dose adequate to 
provide free intracellular methotrexate for a considerable period in 
one tissue, ma,y not suffice even to saturate all of the folic reductase 
in another tissue. 
Burchenal et al (1961) investigated the effect of the administra-
tion of the final amino acid end products of the f olic reductase system 
reactions on the toxicity of methotrexate therapy. They noted that Skipper 
was unable to prevent the inhibiting anti-leukemic effects of methotre-
xate by the administration of tbymidine (TDR), adenine, histidine, methio-
nine and serine either alone or in combination when they were given on a 
three times weekly dosage schedule. Burchenal used various dosages of 
methotrexate in order to find out which of the metabolic pathways inter-
rupted by the drug was responsible for the toxicity. He found that metho-
trexate on a 0.2 mg/kg per dose five times daily for ten days was lethal 
to seventeen of twenty (20) mice. Using this drug dosage schedule, 20 
mg/kg per dose of tbymidine gave no protective effect. The same was true 
of serine, methionine, and histidine at 10 mg/kg. However, adenine at 
10 mg/kg gave complete protection against methotrexate at 0.2 mg/kg., but 
not against 0.4 mg/kg of methotrexate. The addition of tbymidine a.lone 
at 20 mg/kg or of tbymidine plus the three amino acids gave no additional 
protection. They also stated that methotrexate in the mouse and man pro-
duced toxicity at significantly smaller dosages when given by frequent or 
continuous infusion. 
Grant (1958, 1960) using the Rana pipiens erribryo as the experi-
mental system, revealed the effect of antifolic compounds on both DNA and 
RNA. The regions showing the highest mitotic activity, as in mammalian 
tissues, were most easily inhibited by the antagonists. This effect was 
completely prevented by folinic acid in a non-competitive manner. Thy-
17 
midine gave protection at a later stage of de-velopment, but had no pro-
tective effect in the egg stage. He felt that the drug concentration in 
the cells was not enough to interfere with_ the de novo synthesis of RNA, 
but that the tbymidine biosynthesis was sufficientJy inhibited to prevent 
DNA synthesis and accounted for the tissue-specific nature of the observed 
effects. 
Delmonte and Jukes (1962) stated that during methotrexate therapy, 
abnormal chromosomes and mitotic figures were seen which probab]y reflected 
the drug's interference with intracellular nucleic acid synthesis and pro-
vided morphologic evidence of direct damage to the cells of the host. 
However, they also stated that there was no morphologic evidence of direct 
damage to the cell dissolution. 
Risto.logic chan~ 
This section is devoted to the review of microscopic tissue alter-
ations that have been cited following methotrexate therapy in both clini-
cal and experimental settings. 
Skin: 
Van Scott (1963) stated that in the normal process of mitotic 
reduplication, a cell must double its DNA content during the intermito-
tic phase. Since folic acid is essential for DNA synthesis, the effect 
of methotrexate on the epithelium is to prevent or inhibit the cell from 
reaching the state of mitotic preparedness. This is recognizable by the 
rate of mitotic figures observed in a section of tissue per unit time. 
In integument, the process of mitosis is essential to replace those cells 
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that exfoliate and are lost to the external environment. 
In the normal epidermis, the rate of loss of desqua.mated cells is 
such as to require a relatively low rate of mitosis in the single layer 
of germinative cells or basal layer, and histologically, comparatively 
few mitotic figures are found. 
Rothberg et al (1961), using glycine -c14 incorporation into the 
normal stratum corneum as an indicator, found the turnover time of normal 
epidermis to be approximate.ly 27 days. 
Van Scott and Ekel (1963) observed an approximate ninefold increase 
in the number of germinative cells in the basal cell layers, and a 27-fold 
. 
mitotic generation of epidermal cells in the hyperplastic epidermis of 
psoriasis. The skin of the upper back of six patients was chosen and, 
for comparative study specimens, the inner aspect of the lower lip were 
obtained in four of the six patients. They had observed that it was un-
common for the oral mucosa to become involved with psoriasis, even though 
it was continuous with epidermis. They attributed this to the fact that 
the population of germinative cells of the oral mucosa was normally large 
or as they termed it "psoriasiform". 
Mitoses were found to occur in the three lower most cell layers of 
oral mucosa which, as in psoriatic epidermis, are often discernible by 
their deeper stainability. Another similarity of the oral mucosa to 
psoriatic epidermis was that the germinative cell population per unit 
surface of oral epithelium was augmented by undulations of the subrnucosal 
connective tissue papillae. However, the number of mitoses per unit sur-
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face area of mucosa, while it was more than three-fold than in uninvolved 
epidermis, was still less than that in psoriasis. 
Other similar characteristics shared by the oral mucosa and the 
psoriatic skin were parakeratosis, absence of a granular layer, and per-
meability for topically applied substances, all of which seem to be cor-
related with incomplete keratinization secondary to a heightened turnover 
time of the epithelium. 
More recently, an autoradiographic study of the turnover times 
of normal and psoriatic epidermis was done by Weinstein and Van Scott (1965) 
using tritiated tbymidine injected subepidermally. A total turnover time 
of 26-27 days for normal epidermi&was found versus 4 days for that of 
psoriatic epidermis. 
Van Scott' (1963) felt that since the total thickness of the normal 
epidermis is composed of maf.\Y cell layers, af.\Y interference with the mito-
tic replacement during an interval of one or a few days would interfere 
very little with the protective function of this epithelium. Therefore, 
after moderately large doses of the f olic acid antagonists for a limited 
period, grossly detectable skin changes would be minimal in nature. Clini-
cal changes may occur in skin following large doses, but these did not 
seem to result primarily from interference with mitotic replacement of 
the epidermis. 
A limited amount of investigation of methotrexate activity on nor-
mal epithelium has been performed, such as the study of Robinson et al 
(1969). However, the majority of studies on methotrexate action have 
been reported in treatment of psoriasis. Here the turnover time was 
found by Van Scott (1963) to be on1y three to four days. Therefore, he 
felt that psoriatic epidermis, because of its high turnover dynamics, 
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was well-suited for the investigation of methotrexate action; especial1y, 
since this type of epidermis would be exquisitely responsive to the drug 
activity. 
The use of f olic acid antagonists in the treatment of psoriasis 
was introduced by Gubner and August (1951); and the work of Rees and his 
associates (1955, 1959) established that this treatment was effective and 
relatively safe. 
Van Scott and Reinertson (1~59) treated a total of eighteen 
psoriatic patients, 30-76 years of age, with several different chemo-
therapeutic agents, both topical1y and systemically. Six of these were 
given methotrexate 0.5 mg-5 mg/kg in a single intravenous dose and the 
epithelium was observed in conjunction with the following laboratory 
tests: white blood cell count, hemoglobin, platelet count and spermatozoa 
counts (on 2 patients given aminopterin and in two patients given metho-
trexate). All tests were repeated during and after therapy. Scalp hair 
roots were examined during therapy for arry presence of dysplasia. 
The skin biopsies of the treated patients revealed not a single 
cell in mitosis twenty-four hours after the initial injection of metho-
trexate. Within forty-eight hours a few cells in mitosis were found. 
Since keratohyaline granules could be identified in cells of the upper 
malpighian layer and the formation of tonofibrils continued during ther-
apy, 'they concluded that the cytoplasmic activity was undisturbed. 
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The various laboratory procedures disclosed a lowering of the white 
blood cell count and platelets in the peripheral blood. In addition, 
nausea and/or ulceration of the oral mucous membrane occurred. Dysplasia 
of the roots of anagen, or growing hairs was observed, with or without 
hair losses. 
Failure of topical methotrexate, in this study, to affect psoriasis 
locally, suggested to them that its pharmacologic action required initia-
tion at a distant systemic site. 
An interesting finding during their investigation was that spermato-
genesis was depressed. The spermatozoa count depression ranged from 49% 
to 9Cf/o, and the total spermatozoa ~epression ranged between 6']5/o and 97%. 
The sperm counts were done twelve to fourteen d~s after the single intra-
venous dose of methotrexate or oral arninopterin for several repeated 
courses. However, the depression was determined not to be permanent, 
since the two patients who had taken arninopterin, revealed normal counts 
two and three years later. 
Biro et al (1967) in treating psoriatic patients noted that twenty-
four hours following a single 50 mg. intra.muscular dose of methotrexate, 
mitotic figures were no longer prominent with a marked decrease in the 
mitotic index. Pyknotic epidermal cells were found in large numbers in 
the two or three cell layers adjacent to the basement membrane. They 
felt that the location and number of pyknotic cells were suggestive of 
some relationship to the mitotic process. No change was seen in the 
dermis. After 72 hours the mitotic index returned to pre-injection 
levels or higher, and pyknotic cells were virtually absent. Epidermal 
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thickness and acanthosis were measured and no lasting change was produced. 
Halperin and Ohkawara (1967) determined the effects of methotre-
xate on the enzymes of carbohydrate metabolism in psoriatic epithelium. 
They treated five patients with intramuscular methotrexate once a week. 
Many of the enzymes involved in carbohydrate metabolism were assayed 
prior to the treatment and at various times during treatment. They found 
that most of the enzymes measured decreased after therapy and there were 
no specific enzymes which were marked}.y resistant to methotrexate or 
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markedly sensitive to its action. Psoriatic skin and surrounding normal 
appearance skin shared this suppression of enzyme activities. In the 
involved areas, the extent of cli~cal improvement corresponded in gene-
ral to the measurable decreases in enzyme activities. 
From their results, they concluded that methotrexate depressed 
enzyme activities in a rather nonspecific manner. They felt that since 
these enzymes are made by the same mechanism as any other cellular pro-
tein, the action of methotrexate would seem to depress protein production 
in general within the cell. They stated that protein formation was a 
complex process that required activated amino acids, transfer ribonucleic 
acids, ribosomal RNA, messenger RNA and DNA templates. Also necessary were 
an adequate supp]s" of the various enzymes for forming these molecules and 
nucleotides in the form of adenosine or guanosine triphosphate as an 
energy source. 
Since it has been determined that methotrexate binds much more 
strong]s" to the enzyme folic reductase than to folic acid itself, they 
agreed that all these reactions which required tetrahydrof olic acid for 
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their synthetic pathways would be affected. However, they felt that the 
decrease in enzyme levels noted in their treated patients were primarily 
due to a lack of protein synthesis, secondarily to the effect on the DNA 
and RNA synthesis. Yet, they were unable to substantiate this hypothesis 
with experimental proof. 
Another observation of note in their project was an unexpected 
drop in enzyme activities in the uninvolved epidermis of a magnitude com-
parable to that in the involved epidermis. No gross changes were noted 
in the uninvolved skin clinically. 
Gordon et al (1967) treated patients with various agents for psori-
asis, giving two of them 20 mg. methotrexate I.V. weekly and one patient 
methotrexate 2.5 mg orally daily for seven days. Biopsies were taken 
daily for one week, weekly for one month, and then monthly. Skin from 
the back was stained with H and E. They classified the results according 
to the effects noted on each layer of epidermis. The parakeratosis of 
the stratum corneum disappeared by the sixth day after injection of metho-
trexat e. The stratum granulosum assumed a normal appearance by the fifth 
day, and a 78% decrease in the stratum malpighii occurred by day four, but 
then began to increase again. 
They suggested that methotrexate acted mainly through mitotic 
inhibition of the epidermal cells, since there was relatively little 
. change in the inflammatory cell infiltrate or in the blood vessels. 
In addition to the histopathological results, they determined that 
both the epidermal and dermal acid mucopolysaccharides remained consis-
tent and did not show any changes. Only a moderate to minimal reduction 
in the dehydrogenases activities were seen. 
In the realm of animal experimentation, Robinson and Stoughton (1969) 
studied the effect of methotrexate on cell division in the epidermis of 
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4 - 5 day old Sprague-Dawley rats using the mitoses per 1000 interfollicular 
basal cells as an indicator. A dose of 5 mg/kg was administered subcuta-
neously on the ventral surface, and animals were sacrificed at 1/2, 1, 2, 
3, 4, 15 and 24 hours after injection. 
They found an obvious difference in the mitotic activity two hours 
after injection and this depression lasted up to and including the twenty-
four hour group. The "t" test was not significant at the 1/2 and one hour 
times, but the differences were significant at 0.53 from the 2 hour inter-
val and remained so thereafter. There was no significant difference bet-
ween untreated, water or methotrexate treated groups on the mean percen-
tage distribution of the phase of the mitotic cycle recorded. 
In discussingtheir results, they stated that Fukayama (1961) reported 
the minimum c2 time to be about six hours. Thus cells with a double comp-
lement of DNA should be available for mitosis throughout this period. They 
suggested that for some reason c2 cells were unable to enter the mitotic 
cycle in the presence of this dosage of methotrexate. They proposed that 
this might be due to the failure of continuous entry of more cells into 
c2 from the "S" phase, or to some effect on the 1i ttle known processes 
within G2 itself. 
They further mentioned that Pelc (1968) maintained that metabolic DNA 
may be formed in some organs after the "S" phase and before mitosis. 
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However, there is no published information on the formation of metabolic 
DNA in the epidermis of the young rat. 
Other theories on the exact reason for the failure of the onset of 
mitosis with methotrexate include that of Jacobson (1954) in which he felt 
that a lack of high energy compounds such as adenosine and guanosine nuc-
leotides could lead to a failure of DNA, RNA and protein synthesis, there-
by secondarily leading to a failure of mitosis. 
Galper and Darnell (1969) found that methotrexate inhibited the syn-
thesis of formylmethionine S-RNA in the mitochondria of HeLa cells, which 
are of mammalian origin. This observation could give credence to the be-
lief that methotrexate has a direct.effect on the protein synthesis of cells 
as well. 
Fry and McMinn (1966) correlated the findings of methotrexate therapy on 
both the skin and the intestine of psoriatic patients. A dose of 0.5 mg/kg 
methotrexate was administered intramuscularly once a week. They used the 
mitotic skin count and that of the intestinal crypt cells for comparison. 
Ten of twelve patients showed varying degrees of clinical improvement within 
six weeks. Two of three patients showed a decrease in skin counts at three 
hours, and 3 out of 6 by the 24 hour interval. Microscopically, the in-
testinal specimens had normal appearing villi with two of four patients 
eliciting a decreased count at twenty-four hours. 
The presence of degenerate cells with pyknotic nuclei (not included 
in the counts) was regarded by them as evidence of the toxic effect of 
methotrexate on both epidermal and intestinal cells; this was especially 
evident twenty-four hours after the first injection. 
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A marked fall in mitotic index after methotrexate occurred in the in-
testine and the skin, but unlike the psoriatic epidermis, the count of the 
intestinal epithelium returned to the preinjection level by the seventh day. 
They claimed that this observation supported the theory that the '~ealing'' 
action of methotrexate in psoriasis is primarily a direct one on the premi-
totic end mitotic cells of the epidermis. 
Regarding the utilization of the autoradiographic technique for study-
ing the intestine of humans, they felt that injections of thymidine in 
suitable dosage form were impractical, aside from the fact of the ethical 
problem involved in giving a radioactive isotope with a half-life of 
twelve years to patients with a no~-fatal disease. 
Intestine 
The other suitable tissue in which some work has been done with metho-
trexate or tritiated thymidine, and which can be related to the oral muco-
sa, is the intestine. Both animals and humans have been used for inves-
tigation. 
Loehry and Creamer (1969) have investigated the three-dimensional 
structure of the rat small intestinal mucosa,both in the normal state and 
under increased and decreased mitotic conditions. To observe the intestine 
in a repressed turnover state, they used a single 7.5 mg I.M. dose of me-
thotrexate and studied the effects daily for a period of seven days. In 
conjunction with mitotic counting, two rats on day five after methotrexate 
and two normal controls were injected intraperiotoneally with 100 uc of 
tritiated thymidine. One methotrexate and one normal rat were sacrificed 
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after eight hours and the other pair 24 hours after the injection. Auto-
radiograms were prepared on sections of small intestinal mucosa. 
The mitotic counts revealed a marked reduction on days one and two with 
a few mitoses reappearing on day three. By day four to six, a marked 
increase had occurred, a rate greater than that of the normal. Mitotic 
activity returned to normal by the seventh day. 
The tritiated thymidine was administered during the period of regenera-
tion of the intestinal mucosa, day five, so that the eight hour finding 
in the control showed labeling of the crypt cells, while the methotrexate 
treated had occasional labeling at the base of the villi. By the twenty-
3 four hours after H-TDT, the control rats showed labeling approximately 
one third of the way up the villi, whereas, in the methotrexate treated 
animals the lower two-thirds were labeled. The latter observation was 
agreeable with the higher than normal mitotic rate found in the regenera-
ting intestine. 
The height of the labeled villous cell column at twenty-four hours was 
a mean of 22 cells in the control rats compared with a mean of 41 cells 
in the treated group. A standard deviation of 4.3 was present in both 
groups. The difference between the two groups, according to their findings, 
was highly significant (p <o. 001). 
Their investigation showed that a single dose of methotrexate produced 
ci period of diminished cell production for the first three days after injec-
tion, followed by a three day period of increased cell production as the 
mucosa regenerated. Tritiated thymidine was utilized for the "specific 
documentation"of the regeneration period dynamics. 
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In the past, Phillips et al (1949, 1950), using lethal doses of aminop-
terin produced gross cytoplasmic vacuolization of intestinal epithelium in 
the rat, mouse and dog; the epithelial lining of the intestine became des-
quamated with quite extensive leukocytic infiltration of the lamina propria. 
Dustin (1950) noted striking mitotic inhibition of the mouse crypt 
epithelial cells associated with nuclear degeneration, within a few hours 
after lethal doses of aminopterin. A return of mitoses was evident in 
sixty hours, and by ninety-six hours, mitoses appeared normal. 
Vitale et al (1954) administered nonlethal doses of aminopterin to 
rats and observed a reduction in the number of mitoses, degenerated mito-
tic figures, nuclear remnants, and ~isintegrated crypt cells within four 
and one-half hours after injection. Normal mitoses returned 48 hours 
later. 
Trier (1962) reported on the morphologic alteration in the human pro-
ximal small intestine induced by methotrexate therapy of 2-5 mg/kg I.V. 
in fourteen patients without evidence of gastrrointestinal disorders. With-
in three hours after the injection of methotrexate, mitoses per 1000 cells 
were greatly reduced compared to baseline levels. By six to twelve hours, 
mitoses were virtually absent. With this marked inhibition, he noted the 
appearance of discrete, spherical bodies within the cytoplasm of many crypt 
cells~ These bodies ranged from a fraction of a micron to 4 or 5 u in 
diameter and varied considerably in structure. Most of these bodies con-
tained some material which stained intensely with the Feulgen technique, 
indicating DNA probably of nuclear origin. The intracytoplasmic bodies 
were confined exclusively to the crypt region and were never seen in the 
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villous epithelium. Trier noted the identical bodies in the crypt cells 
of a biopsy taken from a patient 20 hours after 100 r of abdominal 
x-irradiation. 
He stated that the mitotic inhibition persisted for approximately 
48 hours, with an increased return of mitoses from 48 - 96 hours, at which 
time they were again normal. 
With light microscopy the architecture of the small intestine did not 
appear to be altered by methotrexate, nor were cytologic changes noted 
anywhere than in the crypt. However, under the electron microscope Trier 
(1916) observed striking dilatation of cisternae of the endoplasmic reti-
culum and Golgi material, swelling witij fragmentation of the micro-villi 
of some mucosal cells, and moderate mitochondrial fragmentati~n occurring 
eight to 48 hours after methotrexate. Adjacent to such damaged cells, mor-
phologically normal appearing cells were seen, and at 96 hours, no struc-
tural alterations were seen. He concluded that methotrexate in a dose 
range of 1.5 to 5.0 mg/kg regularly produced extensive but reversible mor-
phologic alterations of the human small intestinal mucosa, by the inhibi-
tory effect on nucleoprotein synthesis. Also, these changes correlated 
temporally with the period of gastrointestinal toxicity. 
Oral Mucosa 
Shklar et al (1966) in their investigation of the effect of metho-
trexate on chemical carcinogenesis of the hamster buccal pouch, had a 
group of control animals to which only methotrexate was given. A dose of 
0.5 - 0.568 mg/kg was injected subcutaneously three times weekly for a 
period of twelve weeks. They stated that this dosage represented the 
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maximum tolerated dose for this type of animal for the length of their 
study. Higher rated dosages of methotrexate were found to result in the 
deaths of a number of similar experimental animals in observations they car-
ried out prior to this experiment., 
They concluded that methotrexate not only appeared to accelerate the 
formation of tumors in the buccal pouch painted with carcinogenic chemical, 
but acted to produce or develop a more highly anaplastic type of carcinoma. 
The buccal pouches of the methotrexate control groups in their study 
were found to be free of gross pathology. However, microscopically, there 
was some evidence of collagen degeneration in the lamina propria of the 
pouch mucosa of the 12 week group uf animals, 
Two years thereafter, Shklar (1968) gave 0.8 mg/kg of methotrexate to 
20 hamsters six months of age, weighing 115-130 grams. This dose was ad-
ministered subcutaneously three times weekly for four weeks, Sections of 
tongue, palate and gingivae were taken then stained with H and E. He 
found that, although there were no striking gross oral changes visible, 
microscopic examination of the sections revealed a decrease in the width 
of the stratum corneum and a notable degeneration of the collagen bundles 
in the underlying lamina propria, an observation in his earlier project. 
The collagen bundles were clumped and stained more deeply in comparison 
with the control specimens. He concluded that the administration of non-
lethal dosages of methotrexate resulted in collagen degeneration and 
epithelial atrophy of the oral mucosa, thereby possibly explaining the 
occurrence of oral lesions in patients on such therapy. No mitotic counts 
or other criteria were done in this study, nor has any been noted elsewhere 
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in the literature on the effect of methotrexate on the oral mucosa. 
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Drug Application 
Farber et al (1948) were the first to report results of aminopterin 
treatment on five children with acute leukemia. Their study covered a 
period from November, 1947, to April 15, 1948. The original group con-
tained sixteen children, of which ten showed some transient clinical, 
hematologic, and pathologic improvement. The remaining six did not re-
spond. Of the five on which they elaborated, one twelve-year old boy 
developed a stomatitis which interferred with optimal use of the drug. 
Another twelve-year old boy developed minor ulcerative lesions of the 
oral mucosa, resulting in dose reduction. 
Since this initial report, nu~erous clinical applications have been 
investigated. Bertino and Johns (1967) stated that among them are the 
treatment of neoplastic diseases, which include choriocarcinoma, Burkitt's 
lymphoma, palliation of patients with epidermoid carcinoma of the head 
and neck and also of the lung. They mentioned that the use of metho-
trexate in large intermittent doses has produced objective responses in 
about 30 to 50 per cent of the patients treated for head and neck car-
cinoma. However, these responses have been of short duration. 
In addition to the above, methotrexate therapy has been utilized in 
psoriasis (Van Scott, 1964), and more recently, for the suppression of 
the immune response. 
Friedman, Buckler and Baron (1961), using male guinea pigs, revealed 
that methotrexate prevented the development of a delayed skin-hypersensi-
tivity response to diphtheria toxoid when ovalbumin was given as a single 
immunizing dose. 
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Prichard and Hayes (1961) found that no animal receiving both 
aminopterin and bacilli simultaneously developed hypersensitivity, but 
that all controls reacted positively. 
Tobin and Argano (1967) administered a dose of 4 mg./kg. i.p. to 
young adult male mice. In addition, a single dose of tanned sheep red 
cells was given I.V. to the experimental group. Control animals were 
given antigen but were only injected with distilled water intraperito-
neally. Their results indicated that there was significant suppression 
of antibody production in the treated mice when compared with the con-
trol animals. One month later both groups received a second injection 
of sheep red cells, but no additional methotrexate. In this instance, 
they found that the antibody titres were equal in both groups. They 
concluded that in this particular system, methotrexate did not induce 
a permanent refractory state to the antigen, although it was capable of 
suppressing the primary immune response. That is to say, methotrexate 
failed to induce tolerance. From these findings they concluded that 
methotrexate may have therapeutic implications in the treatment of auto-
immune diseases in man. 
Of particular note is the work of Broughton (1967) on homologous 
tooth transplants. He transplanted maxillary and mandibular tooth buds 
from a 50-day fetal guinea pig into the subcutaneous space in the axil-
lary region of adult guinea pigs. This was according to the method of 
Fleming and Soni (1965). 
The experimental guinea pigs were injected with 5 mg. of metho-
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trexate i.p. one day prior to transplantation and daily thereafter for 
three weeks. Then the injections were given every other day until the 
animals were sacrificed. However, the control animals were not given 
injections. On the fifteenth postoperative day and for one month there-
after one guinea pig from each group was sacrificed weekly. 
Histologic examination of the sections of recovered tooth germs 
showed a significant difference between transplants of the two groups. 
The treated group showed normal formation of predentin, dentin, and 
enamel. The inflammatory response was negligible and appeared to have 
little or no effect on the formation of the teeth. However, in the con-
trol group there was evidence of a.severe inflammatory response, resorp-
tion of the dentin, and irregular enamel formation. Therefore, he con-
cluded that methotrexate had suppressed the inflammatory reaction in the 
treated group. 
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Toxicity in Humans and Animals 
The folic acid antagonists primarily affect the more rapidly grow-
ing tissues. Bertino and Johns (1967) stated that the therapeutic index 
in humans is narrow and, in most instances, toxicity of a significant degree 
may result even when the antimetabolite is utilized in therapeutic doses. 
For example, the bone marrow may be depressed and clinical signs of weak-
ness, infection and bleeding may be present. Each of these is related 
respectively to the anemia, granulocytopenia, and thrombocytopenia seen 
with this depression. Pharyngitis, as well as ulcerations of the oral 
and intestinal mucosa may occur. 
Delmonte and Jukes (1962) noted that buccal lesions could precede 
or accompany other symptoms of intolerance. These buccal lesions were 
described as small, shallow, painful, white or yellow, red-edged lesions 
on the lips, tongue, or other oral mucosa. Progression to ulcerative 
lesions followed if therapy was continued. 
The gastrointestinal symptoms of methotrexate toxicity include 
anorexia, abdominal cramps, nausea, and vomiting. Diarrhea, when it 
occurs, is generally a more severe manifestation of drug toxicity. Delmonte 
and Jukes (1962) stated that this usually coincided with the development 
of extensive areas of atrophic degeneration and denudation along the en-
tirety of the lower gastrointestinal tract. They also stated that if 
drug therapy continued after these signs appeared, severe toxicity re-
sulting in death could follow. 
Several minor signs of toxicity with no ulterior sequelae detrimental 
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to the patient are also possible. Among them are brownish skin pigmenta-
tion, erythematous or exfoliative dermatitis, especially on the hands and 
feet, and weight loss. Delmonte and Jukes (1962) felt that this weight 
loss attributed by some to the drug therapy, was probably more a conse-
quence of the tumor patient's cachexia and poor physical condition. 
Van Scott (1957, 1959) stated that transitory alopecia may occur 
with therapy, due to reversible atrophy of anagenetic hair bulbs. 
One of the most interesting aspects of the antifolic compounds is 
their cumulative effect. Rall (1963) stated that while the Ln50 of rats 
given methotrexate in a single dose is about lOOmg./kg., the LD50 for a 
period of fifteen days of administr~tion is only about 0.25mg./kg.--
almost a thirty-fold difference in total dose. 
Philips et al (1950) concluded that on a dose/kg. weight basis, 
methotrexate was tolerated much better in mice, and slightly better in 
dogs, than either aminopterin or dichloromethotrexate--other members of 
the folic acid antagonist family. 
Sullivan (1961) postulated that drug toxicity occurred mainly be-
cause of tissue absorption and prolonged contact of the drug within the 
tissue, and not as a result of drug concentration in the blood. 
Freeman and Narrod (1961) found that following oral and intravenous 
methotrexate, toxicity was related directly to the rate of drug absorp-
tion rather than to the rate of its excretion. They felt that the rate 
of excretion was wholly a consequence of the delayed drug absorption. 
Burchenal (1951) demonstrated that the toxic effects of mcthotrexate 
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overdosage were reversible. He recommended that 3mg. to 12mg. of citro-
vorum factor, the most effective antidote, be given intramuscularly im-
mediately or within four hours of the onset of toxic symptoms. When this 
technique is utilized, the therapeutic effect of the agent is also neutral-
ized. 
The effect of methotrexate on the normal mouse leukocytes has been 
documented by Burchen~l et al (1950). They used 20 gram young male mice 
and administered 3.0 mg,/kg. of the drug intraperitoneally three times 
a week for ten doses. The mice were weighed weekly and the dosage ad-
justed on a weight basis. Control leukocyte and differential counts 
were done before treatment, and re~eated every four days on the surviv-
ing mice. In order that the counts could be done on free-flowing blood, 
the mice were warmed for ten minutes under an electric lamp. Then, a 
small cut was made in a tail vein with a razor blade and the studies 
done on the blood obtained in that manner. Blood smears were stained 
with Wright's stain. 
They revealed that methotrexate appeared to cause only a slight 
leukopenia in normal mice, with no alteration of the differential count. 
This slight leukopenia was replaced by normal leukocyte counts around 
the nineteenth day. These normal counts in the treated animals remained 
relatively stable for the duration of the thirty day experimental period. 
Van Scott et al (1964) have provided evidence that treatment of 
psoriasis with methotrexate 50 mg. intravenously once a week was effec-
tive and would be less toxic than oral therapy of 2.5 mg. daily for six 
days, the recommended dosage schedule. They further stated that oral 
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mucosal ulceration following administration of folic acid antagonists 
seemed to be a direct result of mitotic inhibition where cells normally 
desquamated were not replaced. 
On the other hand, Ryan et al (1964) felt that with low dosage 
schedules of methotrexate mouth ulceration was no more common or con-
sistent than the appearance of mouth ulcers in patients not on folic 
acid antagonists. Once ulcers appeared they may have failed to heal 
unless the folic acid antagonists were discontinued. They proposed 
further that until the cause of the increased turnover of epidermal 
cells in psoriasis was determined, it could not be assumed that the 
demands for folic acid were any greater for nucleic acid synthesis than 
for some of the other enzyme reactions subserving dermal tissue func-
tion, and which could indirectly lead to the increase in mitosis. The 
as yet undetermined amount of folic acid required for the increased 
vasomotor or neuronal activity was also believed to play a role in the 
etiology of psoriasis. 
Van Scott (1963) stated that the eruptions of an erythematous nature 
that may occur during treatment of psoriasis with methotrexate prob-
ably were due to effects of the drug on the small blood vessels. 
As far as the hematologic effect, Vogel (1961) used a dose range 
of 0.2 to 2.25 mg./kg. of methotrexate in his investigation of several 
. antineoplastic compounds in determining their tumor-marrow index. He 
defined the latter as that dose causing 50 per cent destruction of the 
marrow divided by that dose causing 80 per cent suppression of tumor 
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growth in the same animal. He utilized the 6c3HED lymphosarcoma in 
mice for his observations. His obtained value of 3.2 mg./kg. of metho-
trexate was the dose which would cause 50 per cent marrow destruction. 
Sloboda (1960) compared the effect of several folic acid antag-
onists upon mice bearing the 6c3HED lymphosarcoma to establish a quan-
titative means of comparing these compounds. He used the carcinostatic 
index, which he described as the toxic dose/effective dose, to effec-
tively and quickly summarize the attributes of a compound as to its 
effect upon the tumor-bearing mice. He found that a dose of 0.705 mg./ 
kg. of methotrexate produced an efficacy ratio (control/treated) of 2, 
while 2.10 mg./kg. was the dose wh}ch produced a differential weight 
change of 3.4 grams between the control and drug treated animals. 
B. Autoradiography 
The method of autoradiography has be~n described by Fitzgerald 
(1953) as dependent upon the fact that radioactive isotopes may be 
localized to a given area in a histologic section, as well as to in-
dividual cells. The tissue under study is placedsubadjacent to a 
photographic emulsion for an adequate time to allow exposure of the 
emulsion. The emulsion is then developed as in ordinary photography 
and the processed emulsion is then referred to as an autoradiogram. 
It consists of accumulations of silver granules which appear black 
and which overlie the areas in the tissue containing the radioisotope. 
The ionization of the silver bromide crystals contained in the photo-
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graphic emulsion is produced by the rapidly moving charged particles 
emitted from the radioisotopes, thereby permitting the observation of 
the presence of the radioisotope (Schoenheider, 1960). 
Schoenheider (1960) stated that the chemical, as well as the bio-
logical behavior of a substance labeled with a radioisotope were identical 
to that of its stable counterpart provided that the amount of radioacti-
vity that was contained in it was small enough not to have a significant 
radiochemical effect and that the amount of material injected was small 
enough not to produce a significant increase in the amount of the substance 
in circulation. Thus, the labeled substance could be considered a true 
"tracer" of normal in vivo metabolism. 
Hughes et al (1958) stated that tadioactive tritium was an excel-
lent substance to utilize for a label, since very high resolution could 
be obtained; yet, it has very weak energy and a short range of beta rays. 
In tissue the maximum distance a beta ray will travel is six microns, 
and half of the particles will travel less than one micron. Therefore, 
the majority of the activated silver grains of an autoradiogram should 
lie within one micron of their source in the tissue. 
The use of tritium as a tracer substance in autoradiograms is a 
useful adjunct in studying the presence of a chemical substance, such as 
thymidine, or its metabolites in a histologic tissue section. 
Lajtha, Phil, and Oliver (1959) concluded that thymidine was a 
specific component of DNA, since it labeled only DNA. Tritium was 
determined to have a half life of 12.26 years and a disintegration rate 
of 0.0063 per day. 
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Messier and Leblond (1960) stated that the synthesis of DNA is 
known to occur before mitosis. Therefore, if the radioactive precursor 
were given at that time, the nucleus would become radioactive and, using 
radioautography, could be noted even before mitosis occurs. These nuclei 
retained the label of radioactivity and passed it on to the daughter cells 
during mitosis. Therefore, tritiated thymidine is a valuable compound 
for the detection of newly formed DNA by the method of autoradiography. 
In their study they reported on the labeled nuclei in the mouse 
tongue and epidermis after eight hours, twenty-four hours, and seventy-
two hours from the initial tritiated thymidine injection. They investiga-
ted the various rat tissues more extensively with additional detailed 
time interval observations. Since methotrexate is known to interfere 
with DNA synthesis, the autoradiographic method is a most accurate one 
for the determination of the specific effect of this drug on the oral muco-
sa. 
CHAPTER III 
MATERIALS AND METHODS 
Fifty-two adult male mice, Swiss-Webster strain,weighing an average 
of 25 grams, and on a diet of Purina Chow for mouse or rat, were used. 
Food and water were given ad libitum. Blood for initial and final white 
blood cell counts, and differential Wright's blood smears were obtained 
by cutting off the tip of the tail of each mouse and aspirating blood into 
1 cc. disposable syringe. Weights were taken initially, periodically du-
ring the six-day injection period,.and at the time of sacrifice. Metho-
trexate dosage was adjusted according to a weight basis. 
The experimental mice, 26 in number, were injected intraperitoneally 
with a therapeutic dose of 2.5 mg/kg of a 1.53 starch solution of Methotrex-
ate Sodium (supplied by Lederle Laboratories, Adolph E. Sloboda, Ph.D., 
Pearl River, N.Y.) daily for a period of six days. Twenty-six control 
mice were injected intraperiotoneally with 0.4 cc. sterile water daily for 
the same period. Then, on the seventh day both groups were injected intra-
peritoneally with 50 uc. of tritiated thymidine (supplied by Schwarz Bio-
research, Orangeburg, N.Y.) and were sacrificed at intervals of 15, 30, 
45 and 60 minutes, 2, 3, 4, S, 6, 7,8,9, 10, 12, 14, 16, 18, 20, 24, and 
.48 hours following the injection. 
The tongue and palate were dissected out on each mouse, fixed in for-
malin, dehydrated, and embedded in paraffin. 
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Sections of the tongue and palate, cut at 5 microns were prepared. Three 
slides from each sacrifice period were selected for autoradiography. Addi-
tional sections of each tissue from each time interval were stained by the 
Hematoxylin and eosin method. 
Autoradiographic Technique 
The autoradiographic technique used was modified from that described 
by Fitzgerald (1961). Under darkroom conditions, a Wratten #2, Red Safe-
light 25 watt bulb was used. A humidity of 703 and below was sustained. 
The slides were dipped in Kodak NTB3 liquid emulsion (supplied by Eastman 
Kodak, Rochester, N.Y.) and were air dried for 10 minutes. Ten slides were 
placed in a black lightproof exposure box, section sides up. Lithium chlo-
ride was placed in the box for maitaining a low humidity, and black plas-
tic tape was used to seal the box. It was exposed for 10 days at low humi-
dity and temperature. During the exposure time, the box must be maintained 
in a position which keeps the sections upright. After the 10 day period, 
the slides were placed in a staining rack and developed for five minutes 
at 60°F (18°c) in Kodak Dl9 developer. The slides were rinsed in distilled 
water for 30 seconds and then placed in acid fixer for 10 minutes. Fol-
lowing this, the slides were rinsed in running tap water for 30 minutes. 
Both the staining dish and slides were covered with tissue paper to prevent 
dust from settling on them and allowed to dry in a stream of air. The 
processed autoradiograms were then stained with nuclear fast red and counter-
stained with indigo carmine. 
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Cell Population 
An area of 100 basal cells in length was determined and the correspon-
ding numbers of total epithelial cells it represented was found. This was 
then adjusted for a total population of 1000 epithelial cells. For each 
time interval, 2-4 slides were utilized. 
Percentile of Labeled Nuclei 
Under high dry magnification 500 basal cell fields were counted. The 
number of labelled nuclei observed in an area of 1000 cells were recorded, 
and from this, the mean and standard deviation were determined. The per-
centages were converted to log 10 for the preparation of a curve (Figs. 4-5). 
CHAPTER IV 
FINDINGS 
Within one hour after injection of tritiated thymidine, an average of 
9.833 and 10.553 of the stratified squamous epitheUalcells in the tongue 
and palate, respectively, were labeled in the control animals. The expe-
rimental mice showed an average of 15.603 labeled nuclei in the tongue and 
24.243 in the palate during the same interval. (tables I,II) 
The number of labeled nuclei in the tongue doubled from an average of 
9.833 to 19.403 by the six hour period in the control animals. The experi-
mental group showed a doubling of 15.603 to 32.753 in the number of epithe-
lial cells in the tongue an hour later (7 hours). (Table I) 
In the palate of the control group the number of labeled nuclei doubled 
from 10.553 to 27.503 by the sixth hour after injection of the tritiated 
thymidine. The experimental group showed doubling of labeled cells from 
24.243 to 45.303 by the eight hour period. (Table II) 
The labeled cell values continued to climb and reached a peak of 73.803 
and 67.303 in the control tongue and palate, respectively,during the 10-14 
hour interval. 
In the experimental animals the level of labeled cells reached a pla-
teau around 273 in the tongue and 43% in the palate within the 10-14 hour 
period. 
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During the 12-24 hour interval the control group showed a gradual 
decline in the number of labeled epithelial cells, while that of the 
experimental group showed a recovery by maintaining an average of 253 
labeled cells in the tongue and 343 in the palate. (Fig. 4-5) By the 
end of 24 hours the total number of labeled nuclei in both control and 
experimental groups were comparable. 
The total white blood cell counts of the control group showed only 
interpersonal variation and did not increase or decrease significantly 
during the experimental period. (Table III) On the other hand, the counts 
of the treated group were found significantly to decrease 193 during the 
six day treatment period. (Table IV) The differential white blood cell 
count did not vary from the normal. 
Upon comparison of the initial white blood cell counts of the control 
and experimental animals a "t" value of 0.113 was obtained. A similar 
comparison of the initial and final control counts gave a '~" value of 
0.484. (Table III) However, when the initial and final white blood cell 
counts of the experimental animals were analyzed, a "t" value of 1. 783 at 
50° levels of freedom was found to be significant (0.05 P 0.025). 
(Table IV) 
Throughout the six-day treatment period no significant weight loss 
was noted. (Table V) 
CMTimV 
DISCUSSION 
Stratified squamous epithelial tissues from the tongue and palate of 
the mouse have been investigated in regard to the specific effect of metho-
trexate upon these tissues. 
During the first hour after injection of tritiated thymidine, the 
control animals showed an average of 10% labeled epithelial nuclei versus 
163 and 24% in the experimental animals. This indicated that there was 
initially a greater residue of inh}bited cells in the rnethotrexate treated 
animals; that is, many cells in the experimental group were unable to pro-
ceed with DNA synthesis and continue into mitosis, since they were thy-
rnidine deficient. However, upon injection of the tritiated thymidine, 
these inhibited cells did accept the thymidine, but still were unable to 
proceed immediately into mitosis, as was evident by the delay in doubling 
time of one hour in the tongue and two hours in the palate. 
The actual time of doubling occurred between 6 - 14 hours in the control 
group and 7 -14 hours in the experimental group. This is evident since 
the labeled cell values continued to climb, especially in the control group, 
until a peak was reached during the 10 - 14 hour interval. (Fig. 4-5) 
However, at 10 hours only 233 of the experimental cells were labeled as 
compared to 47% of the control group. This showed that the control animal 
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cells were free to continue mitosis while the experimental cells were 
suppressed. Therefore, methotrexate at this therapeutic dosage was effect-
ive in inhibiting the epithelial cells since they were not labeled, and 
a resultant delay into mitosis was observed. 
The actual doubling time, as derived from the continued increase in 
labeled values after 6 hours in the control group, agrees with the findings 
of Schoenheider (1960) who reported a doubling time of eleven hours in the 
stratified squamous epithelium of the ventral surface of the tongue in the 
mouse. Dhawan (1964) also found a peak of labeled epithelial cells in the 
ventral surface of the tongue at 10 hours. He reported a doubling time of 
8 - 10 hours in the epithelium of ~he palate in mice. Joglekar (1964) 
agreed with these findings in her study of the normal mouse interdental 
papillae. 
The delay in doubling time of one to two hours found in the tongue and 
palate is supported by previous investigations of methotrexate inhibition 
upon DNA synthesis and mitosis in the epidermis and intestinal mucosa of 
both humans and animals. Robinson and Stoughton (1969) observed depressed 
mitotic activity in the epidermis within two hours after a dose of 5 mg/kg 
of methotrexate in 4 - 5 day old rats. Fry and McMinn (1966) noted a marked 
decrease in the mitotic counts of the skin and intestine of psoriatic pa-
tients as early as three hours after methotrexate administration. Trier 
(1962) reported greatly reduced mitotic counts in human intestine within thre1 
hours after drug injection. 
The fact that the epithelial cells of the experimental animals in this 
study elicited a recovery of mitotic activity during the 12 - 24 hour 
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interval might be explained by Werkheiser (1963) who maintained that as 
long as a sufficient level of methotrexate was present, all the available 
folic reductase enzyme would be bound. However, as time progressed, the 
concentration of the drug diminishes and newly formed enzyme could be 
utilized to continue DNA synthetic pathways. The formation of new enzyme 
can occur since it is essentially protein synthesis, which is not greatly 
reduced by the presence of methotrexate. 
During the six day treatment period no significant weight loss was 
noted (Table 5). This is in contrast to Sloboda (1960) who stated that 2.10 
mg/kg of methotrexate for six days produced a differential weight change 
of 3.4 gms between control and tre~ted animals. However, his study also 
involved the 6C3HED lymphosarcoma in the mice, and it may be assumed that 
the weight change was due to influencing factors other than methotrexate, 
as also stated by Delmonte and Jukes (1962). 
The depression of the total white blood cell count by 193 found in this 
investigation demonstrated that 2.5 mg/kg of metho~rexate is a therapeutic 
dosage and is agreeable with the findings of Vogel (1961) who reported some 
marrow destruction from a comparable dosage of methotrexate. 
The fact that no significant change occurred in the differential count 
of the experimental animals coincides with the results of Burchenal et al 
(1950). They concluded that with a 3.0 mg/kg dose of methotrexate given 
three times a week to mice, no alteration in the differential count occurred. 
The present investigation has shown that tritiated thymidine adminis-
tration may serve as a model for studying the effect of a therapeutic dosage 
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of rnethotrexate for a period of six days upon the tongue and palate of the 
mouse. 
CHAPTER VI 
SUMMARY 
Twenty-six adult male mice, Swiss-Webster strain, were maintained on 
a therapeutic dose of methotrexate sodium, 2.5 mg/kg, daily for a period 
of six days. Twenty-six similar control mice were injected intraperito-
neally with 0.5 cc. sterile water for injection daily for the same period. 
On the seventh day both groups were injected with 50 uc. of tritiated 
thymidine and were sacrificed at twenty intervals between fifteen minutes 
and forty-eight hours. 
The tongue and palate were sectioned at 5 microns, and the sections 
were stained with hematoxylin and eosin. Additional mounted sections also 
were used to expose a coating of Kodak nuclear track emulsion NTB3 for ten 
days, followed by development of the sections and staining with nuclear 
fast red and counterstaining with indigo carmine. 
The number of labeled nuclei in the basal and subsequent layers were 
counted for each time interval. 
At fifteen minutes labeled nuclei were observed in the epithelium of 
the ventral surface of the tongue and of the palate in a random distribu-
tion. Within one hour an average of 103 of the control group tongue and 
palate were labeled as compared to 163 and 243 in the methotrexate treated 
tongue and palate, respectively. Through mitosis the cells had doubled 
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in number within six hours in the control animal tongue and palate. In the 
experimental animals the doubling occurred at seven hours in the tongue and 
eight hours in the palate. 
The total white blood cell counts of the treated group decreased sig-
nificantly by 193 
Throughout the six day treatment period no significant weight loss was 
noted. 
CHAPTER VII 
CONCLUSIONS 
Ten per cent of the cells in the tongue and palate of the control ani-
mals were labeled within one hour. In the experimental group an average 
of 15.603 of the cells in the tongue and 24.243 of those in the palate were 
labeled within the first hour after injection. 
The basal cell population which had undergone DNA synthesis doubled in 
number in six hours in the control tongue and palate. Doubling in the 
experimental tongue and palate occurred in seven and eight hours, respec-
tively. 
Methotrexate at a therapeutic dosage of 2.5 mg/kg was shown to inhibit 
the epithelial cells in the mouse tongue and palat~ since at 10 hours only 
an average of 233 of the experimental cells were labeled as compared to 
473 in the control group tissues. 
The white blood cell differential count did not change significantly 
in the experimental animals, while the total white blood cell count did 
decrease by 193. 
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APPENDIX 
TABLE I 
PERCENTILE OF LABELED CELLS IN STRATIFIED SQUAMOUS EPITHELIUM 
OF THE VENTRAL SURFACE OF THE TONGUE IN ADULT MICE 
Time Control Log Experimental Log 
Interval Percent Percent Eercent Percent 
15 minutes 12.35 1.092 13.25 1. 125 
30 minutes 8.10 0.909 17.15 1.233 
45 minutes 11. 77 1.075 14.75 1.167 
1 hour 7.12 0.853 17.25 1.236 
2 hours 14.30 1.155 14.37 1.155 
3 hours 7.87 0.896 17.00 1.230 
4 hours 6.00 0.778 16.25 1.210 
5 hours 5.40 0.073 
6 hours 19.40 1.288 
7 hours 16.25 1.210 32.75 1. 515 
8 hours 19.50 1.290 22.00 1.342 
10 hours 43.00 1.634 24.00 1.380 
12 hours 73.80 1.868 
14 hours 39.00 1.591 27.50 1.439 
16 hours 16.25 1.212 
18 hours 30.50 1.484 
20 hours 11.20 1.049 2.00 0.031 
24 hours 51.60 1. 713 
Mean 22.75 Mean 18.03 
Standard Standard 
Deviation 19.21 Deviation 16.73 
"t" = 0. 692 
O. 25>p>O· 20 
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TABLE II 
PERCENTILE OF LABELED CELLS IN STRATIFIED SQUAMOUS EPITHELIUM 
OF THE PALATE IN ADULT MICE 
Time Control Log Experimental Log 
Interval Percent Percent Percent Percent 
15 minutes 12.12 1.097 28.30 1.447 
30 minutes 2.60 0.042 18.95 1.277 
45 minutes 18.45 1.265 5.30 0.074 
1 hour 9.00 0.095 25.48 1.407 
2 hours 15.80 1.199 26.98 1.430 
3 hours 5.65 0.075 14.14 1.155 
4 hours 5.60 0.075 9.30 0.097 
5 hours 14.60 1.165 
6 hours 27.50 1.439 
7 hours 25.00 1.39!3 28.60 1.447 
8 hours 5.30 0.072 45.30 1.653 
10 hours 51.30 1.708 21.67 1.322 
12 hours 67.30 1.826 
14 hours 44.60 1.644 43.30 1.637 
16 hours 22.00 1.342 
18 hours 36.00 1.556 
20 hours 4.67 0.067 6.00 0.078 
24 hours 88.40 1.945 
Mean 25.56 Mean 23.06 
Standard Standard 
Deviation 25, 16 Deviation 11. 87 
"t II = 0.335 
0.35>p>O. 30 
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TABLE III 
TOTAL WHITE BIDOD CELL COUNI'S IN THE CONI'ROL MICE 
Time Interval 
15 minutes 
30 minutes 
45 minutes 
1 hour 
2 hours 
3 hours 
4 hours 
5 hours 
6 hours 
7 hours 
8 hours 
10 hours 
12 hours 
14 hours 
16 hours 
18 hours 
20 hours 
24 hours 
48 hours 
Initial (C.) 
cu/mm blooa 
8,400 
9,256 
14,220 
10,950 
22,750 
14,800 
9,600 
13,250 
16,000 
9,250 
7,600 
8,500 
7,900 
11,474 
10,474 
10,300 
5,200 
9,374 
12,220 
19,320 
14,420 
45,600 
6,920 
20,150 
14,420 
26,350 
Mean 13,796 
Standard 
Deviation f'/J78 
Ci vs. Cf : 11t 11 = 0.0484 
o.4875>P> o.475 
11 t 11 = 0.113 
Final (Cf) 
cu/mm blood 
22,560 
6,400 
9,000 
15,300 
14,650 
15,350 
11,700 
8,550 
9,700 
11,500 
5,400 
13, 150 
12,400 
19,850 
5,800 
14,250 
12,500 
36,750 
8,450 
9,600 
13,200 
19,200 
15,300 
19,850 
10,550 
15,000 
Mean 13,306 
Standard 
Deviation qoso 
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TABLE "IV 
TOTAL WHITE BI.DOD CELL COUNTS IN THE EXPERIMENTAL MICE 
Time Initial(Ei) FinalCEr) 
Interval cu/mm blood cu/mm blood 
15 minutes . 12,.500 20,700 
19,2.50 15,900 
)0 minutes 21,000 7,600 
11,450 7,950 
19,300 14, 750 
45 minutes 8,900 7,700 
22, 150 9,050 
1 hour 13,300 8,500 
10,950 10,050 
2 hours 8,150 19,800 
12,200 24,600 
3 hours 1r,200 10,450 
6,000 9,700 
4 hours 7,150 2,350 
5 hours 27,850 7,550 
6 hours 11,750 14, 150 
7 hours 14,500 10,650 
8 hours 17,850 8,100 
10 hours 7,450 11,250 
12 hours 11, 150 8,000 
14 hours 15,950 10,850 
16 hours 10,400 8,050 
18 hours 17,200 16,750 
20 hours 9,750 4,600 
24 hours 9,850 9,500 
48 hours 9,850 7,700 
Mean 13,578 Mean 10,992 
Standard Standard 
Deviation 5,245 Deviation 5,007 
Ei vs. Ef : "t'' = 1. 783 
o.05>p>o.025 
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TABLE V 
WEIGHTS OF CONTROL AND EXPERIMENTAL ANIMAIS 
Time Interval Control Experimental 
Initial Final Initial Fina.l 
Gms. Gms. Gms. Gms. 
15 minutes 23.0 24.7 27.7 27.8 
25.6 24.1 23.5 20.7 
30 minutes 27.3 27.5 23.9 23.3 
22.1 21.5 24.4 22.5 
24.5 27.2 27.0 26.6 
45 minutes 27.5 26.6 28.3 28.9 
22.5 20.9 24.9 25.6 
1 hour 25.6 26.0 21.9 21.7 
23.2 21.5 29.3 28.3 
2 hours 27.9 28.4 24.5 23.4 
22.4 22.4 24.o 21.7 
3 hours 24.7 26.5 23.2 23.6 
28.3 26.6 25.8 27.8 
4 hours 25.7 27.2 27.7 22.3 
5 hours 24.8 22.1 21.6 19.5 
6 hours 22.7 22.3 31.7 30.3 
7 hours 25.3 25.0 26.6 26.9 
8 hours 25.1 25.5 28.6 29.4 
10 hours • 23.2 23.2 28.7 23.2 
12 ho'urs 22.0 22.1 22.7 21.3 
14 hours 22.2 21.0 25.8 24.8 
16 hours 23.1 23.2 24.5 23.2 
18 hours 26.8 24.4 27.1 27.3 
20 hours 23.4 22.2 27.1 27.3 
24 hours 25.1 25.1 24.6 23.6 
48 hours 24.0 21.9 22.0 22.6 
Mean 24.5 24.2 Mean 25.6 23.9 
Standard Standard 
Deviation 1.87 2.26 Deviation 2.51 5.54 
c vs. E fina.l weights : "t" = 0.288 
0.40>p~O.J5 
a) 
b) 
o) 
FOLIC ACID (PGA) 
Pteroylglutamic Acid 
C'OON 0 
I ••~ Mc-N-C--~~-CH2 
I H "K 
~ .. 2. 
CH1. 
I 
COOM AMINOPTERIN (AMP) 
4-aminopteroylgluta::nic Acid 
METHOTREXATE (MTX) 
4-amino-N10_metbylpteroylglutamic Acid 
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BIOSYNTHESIS OF THYMIDYLIC ACID: 
Role of tetrahydrofolate coenzyrnes * 
*Adapted from: Mead (1963), P• 937. 
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Horizontal scale is Time in Hours. Vertical scale is Log 3 of Labeled Epithelial Cells. 
Black line denotes control animals, while red line represents the experimental animals. 
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PERCENTAGE DISTRIBUTION OF LABELED STRATIFIED SQUAMOUS EPITHELIAL CELLS OF THE PALATE 
Units, labels, and scales are identical to those used in Figure 4. 
FIGURE 5 
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